Orbis Medicines Enters Drug Discovery Partnership With Novo Worth Up To $1.4 Bln - NVO News | RalliesOrbis Medicines Enters Drug Discovery Partnership With Novo Worth Up To $1.4 Bln
N
NVO• Orbis Medicines and Novo Nordisk partnership
- Novo Nordisk will make a strategic investment in Orbis Medicines.
- The agreement includes additional tiered royalties on future product sales.
- The collaboration will develop orally bioavailable macrocycle drug candidates for cardiometabolic targets.
- Orbis Medicines said it has entered a multi-target drug discovery partnership with Novo Nordisk worth up to $1.4 billion.
